Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

Brasilia University Hospital15 enrolled

Overview

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life. Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.

Study Type

INTERVENTIONAL

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Bradycardia Hypotension

Interventions

RemifentanilDRUG

bolus dose

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Indication of anesthesia induction Exclusion Criteria: * Protocol violation * Monitoring problems

Locations (1)

Hospital das Forças Armadas

Brasília, Federal District, Brazil

Outcomes

Primary Outcomes

hemodynamic stability during rapid sequence intubation

no bradycardia and no hypotension

Time frame: from anesthesia induction up to 5 minutes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.